Modified hepatocyte growth factor gene therapy - ViroMed

Drug Profile

Modified hepatocyte growth factor gene therapy - ViroMed

Alternative Names: HGF-X7; NL003; VM 202; VM202-ALS; VM202-CAD; VM202-DPN; VM202-PAD; VM202-Stent; VM202RY

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator ViroMed Co Ltd
  • Developer Beijing Northland Biotech; Reyon Pharmaceutical; ViroMed; ViroMed Co Ltd
  • Class Gene therapies; Growth factors; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Amyotrophic lateral sclerosis
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Diabetic neuropathies
  • Phase II Peripheral arterial disorders
  • Phase I/II Amyotrophic lateral sclerosis
  • Phase I Ischaemic heart disorders; Myocardial ischaemia

Most Recent Events

  • 09 Feb 2017 US FDA approves IND application for VM 202 in Amyotrophic Lateral Sclerosis
  • 09 Feb 2017 US FDA approves IND application for VM 202 in diabetic foot ulcer
  • 09 Feb 2017 Adverse events data from a phase I/II trial in Amyotrophic lateral sclerosis released by VM BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top